NEW YORK, November 16, 2016 /PRNewswire/ --
Stock-Callers.com brings its focus back on the Services sector which
Pennsylvania headquartered Rite Aid Corp.'s shares rose 3.03% and finished Tuesday's trading session at $7.48. A total volume of 17.19 million shares was traded, which was above their three months average volume of 16.23 million shares. In the last one month, the stock has advanced 6.25%. The Company's shares are trading above their 50-day moving average by 1.49%. Moreover, shares of Rite Aid, which through its subsidiaries, operates a chain of retail drugstores in the US, have a Relative Strength Index (RSI) of 61.70.
On November 14th, Rite Aid announced that Rite Aid stores nationwide would now offer American Express Card Members participating in the Membership Rewards® program the opportunity to use Membership Rewards® points for eligible purchases. Eligible American Express Card Members, who have accumulated enough Membership Rewards® points to pay for their purchase, will be prompted to use points for their purchases after they swipe, tap or insert a Membership Rewards-enrolled American Express Card in-store. Rite Aid is the first pharmacy chain to offer Card Members the opportunity to use Membership Rewards® points for their purchases. Sign up and read the free research report on RAD at:
Walgreens Boots Alliance
On Tuesday, shares in Deerfield, Illinois-based Walgreens Boots Alliance Inc. recorded a trading volume of 6.50 million shares, which was higher than their three months average volume of 4.48 million shares. The stock ended the session 1.86% higher at $83.28. The Company's shares have gained 6.76% in the last one month and 0.92% in the previous three months. The stock is trading 2.91% and 3.67% above its 50-day and 200-day moving averages, respectively. Furthermore, shares of Walgreens Boots Alliance, which operates as a pharmacy-led health and wellbeing company, have an RSI of 59.82.
On October 31st, 2016, research firm Wells Fargo initiated an 'Outperform' rating on the Company's stock.
As per notes filed with the SEC on November 04th, 2016, Walgreens Boots Alliance entered into an Underwriting Agreement on November 1st, 2016, with affiliates of Kohlberg Kravis Roberts & Co. L.P. (the "Selling Stockholders") and Goldman, Sachs & Co. with respect to a registered underwritten public offering of 20,461,215 shares of the Company's common stock, par value of $0.01 per share, to be sold by the Selling Stockholders. The complimentary research report on WBA can be downloaded at:
Shares in Dublin, Ohio headquartered Cardinal Health Inc. closed the day at $71.39, down 1.33%. The stock recorded a trading volume of 4.45 million shares, which was above its three months average volume of 2.73 million shares. The Company's shares are trading 4.22% below their 50-day moving average. Additionally, shares of Cardinal Health, which operates as a healthcare services and products company worldwide, have an RSI of 49.83.
On October 28th, 2016, research firm Robert W. Baird downgraded the Company's stock rating from 'Outperform' to 'Neutral'. The research firm also revised downwards its previous target price from $92 to $82.
On November 03rd, 2016, Cardinal Health announced that its board of directors approved a regular quarterly dividend of $0.4489 per share, payable January 15th, 2017, to shareholders of record on January 3rd, 2017. Register for free on Stock-Callers.com and access the latest report on CAH at:
At the closing bell yesterday, shares in Pittsburgh, Pennsylvania headquartered GNC Holdings Inc. ended 1.01% lower at $14.75 and with a total trading volume of 1.84 million shares. The stock is trading below its 50-day moving average by 21.60%. Shares of the Company, which together with its subsidiaries, operates as a specialty retailer of health, wellness, and performance products, have an RSI of 38.61.
On October 27th, 2016, GNC Holdings reported consolidated revenue of $628.0 million, a decrease of 8.1% as compared with consolidated revenue of $683.4 million for Q3 2015. The company's same store sales decreased 8.5% in domestic company-owned stores (including GNC.com sales) in Q3 2016. For the reported quarter, the Company reported net income of $32.4 million compared with net income of $45.8 million in Q3 2015.
On October 28th, 2016, research firm Deutsche Bank reiterated its 'Hold' rating on the Company's stock with a decrease of the target price from $22 a share to $16 a share. Get free access to your research report on GNC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All